SWOG clinical trial number
S1607

A Phase II Study Of Combining Talimogene laherparepvec (T-VEC) And PD-1 Blockade With Pembrolizumab In Patients With Advanced Melanoma Who Have Progressed On Anti-PD1 Therapy

Open
Phase
II
Accrual
38%
Abbreviated Title
T-VEC + Pembro in Adv Melanoma follow prog on PD-1 Inhibitor
Status Notes
Effective 10/02/2017 at 2pm Eastern, S1607 will be active for accrual.
Activated
10/02/2017
Participants
CTSU, US INSTITUTIONS ONLY, ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE

Research committees

Melanoma

Treatment

MK-3475 Talimogene Laherparepvec

Eligibility Criteria Expand/Collapse

**Patients must have**:
-pathologically confirmed Stage IV or unresectable Stage III melanoma (see Section 4.0). Patients must not have disease that is suitable for local therapy, administered with curative intent.
-measurable disease per RECIST 1.1 (see Section 10.1). Contrast-enhanced CT scans of the chest, abdomen and pelvis are required. A whole body PET/CT scan with diagnostic quality images and intravenous iodinated contrast may be used in lieu of a contrast enhanced CT of the chest, abdomen and pelvis. Imaging of the head and neck is required only if the patient has a head/neck
S1607
Page 39
Version Date 7/13/18
lesion. Contrast may be omitted if the treating investigator believes that exposure to contrast poses an excessive risk to the patient. If skin lesions are being followed as measurable disease, photograph with a ruler included and physician’s measurements, must be kept in the patients chart as source documentation. All measurable lesions must be assessed within 28 days prior to registration. Tests to assess non-measurable disease must be performed within 42 days prior to registration. All disease must be assessed and documented on the Baseline Tumor Assessment Form (RECIST 1.1).
-Cohort A: Patients must have at least one measurable visceral lesion (per RECIST 1.1). A visceral lesion is any solid organ except for skin, lymph node, and musculoskeletal tissue. At least one of these visceral lesions must be measurable per RECIST 1.1.
-Cohort B: Patients must not have any visceral lesions.
-Patients must, in the opinion of the treating physician, be candidates for intralesional administration into cutaneous, subcutaneous, or nodal lesions. Patients must have at least 2 injectable lesions.
- Patients may have brain metastases if all lesions have been treated with stereotactic radiation therapy, craniotomy, or gamma knife therapy with no evidence of progression (demonstrated by identical imaging modality for 2 consecutive assessments/scans (MRI or CT scans), at least 4 weeks apart) and have not required steroids for at least 14 days prior to registration.

Patient must have had prior treatment with anti-PD-1 or anti-PD-L1 agents and have documented disease progression on these agents prior to registration (see Section 18.1 for a list of these agents).
b. Patients must not have had surgery, biologic therapy, or hormonal therapy within 14 days prior to registration. Patients must not have had chemotherapy, targeted small molecule therapy, or radiation therapy within 14 days prior to registration. Patients must not have had a monoclonal antibody, except anti-PD1/L1 antibodies, within 28 days prior to registration.
-Patients must have recovered from all adverse events due to prior anti-cancer therapy (residual toxicity ≤ Grade 1) prior to registration, with the exception of patients with ≤ Grade 2 neuropathy, ≤ Grade 2 hypothyroidism, or ≤ Grade 2 alopecia.
--- If patients received major surgery, they must have recovered adequately from toxicity and/or complications from the intervention prior to registration.
-Patients must not have received prior treatment with talimogene laherparepvec (T-VEC) or other oncolytic virus agents.
- Patients must not have received any live vaccine within 30 days prior to registration. Seasonal flu vaccines that do not contain live virus are permitted.
-Patients must not be planning to receive other biologic therapy, radiation therapy, hormonal therapy, chemotherapy, surgery, or other therapy while on this protocol. Palliative radiation therapy or surgery can be considered for symptomatic non-target lesions after discussions with the study team.
-Patients must be ≥ 18 years of age.
- Patients must have Zubrod Performance Status ≤ 2.
- Patients must have adequate hematologic function as evidenced by all of the following within 28 days prior to registration: ANC ≥ 1,500/mcL; hemoglobin ≥ 8 g/dL; platelets ≥ 100,000/mcL.
- Patients must have adequate hepatic function as evidenced by all of the following within 28 days prior to registration: albumin ≥ 2.5 g/dL, total bilirubin ≤ 1.5 x Institutional Upper Limit of Normal (IULN) except patients with documented Gilbert’s Syndrome (≤ 3 x IULN is eligible); AST and ALT both ≤ 3 x IULN.
- Patients must have LDH obtained prior to registration.
- Patients must have complete physical examination and medical history obtained within 28 days prior to registration.
-- Patients must not require use of systemic corticosteroid within 14 days prior to registration or during protocol treatment. Patients with preexisting severe autoimmune disease requiring systemic corticosteroids or ongoing immunosuppression are not eligible.
- Patients must not have known history of hepatitis B, hepatitis C, or HIV due to contraindication of talimogene laherparepvec (T-VEC) in immune-compromised patients and that administration of talimogene laherparepvec (T-VEC) has not been tested in HIV-positive patients. The use of physiologic doses of corticosteroids may be approved after consultation with the Study Chair.
-Patients must not have history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
- Patients must not have an active infection requiring systemic therapy nor a viral infection requiring intermittent treatment with an antiherpetic drug, other than intermittent topical use.
-Patients must not have active herpetic skin lesions or prior complications of herpetic infection (e.g., herpetic keratitis or encephalitis) which requires intermittent or chronic treatment with an anti-herpetic drug other than intermittent topical use.
- Patients must not have organ allografts.
-Patients must not have an uncontrolled intercurrent illness or whose control may be jeopardized by the treatment with the study therapy, or psychiatric illness/social situations which would limit compliance with study requirements.
- Patients must not have history or evidence of active autoimmune disease (e.g., pneumonitis, glomerulonephritis, vasculitis, or other) that requires systemic treatment (i.e., use of corticosteroids, immunosuppressive drugs or biological agents used for treatment of autoimmune diseases). Replacement therapy (e.g., thyroxine for hypothyroidism, insulin for diabetes or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment for autoimmune disease.

-Patient must not have evidence of any clinically significant immunosuppression such as the following:
---Primary immunodeficiency state such as Severe ---Combined Immunodeficiency Disease;
---Concurrent opportunistic infection;
Receiving systemic immunosuppressive therapy (>2 weeks) including oral steroid doses >10 mg/day of prednisone or equivalent within 2 weeks prior to enrollment.
- No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for two years.
- Patients must not be pregnant or nursing due to risk of fetal or nursing infant harm. Women of reproductive potential must have a negative serum pregnancy test within 7 days prior to registration. Women/men of reproductive potential must have agreed to use an effective contraceptive method while on study and for 120 days after last study treatment. A woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures.
---Specimen Submission Criteria
- Patients must be willing to submit blood and tissue specimens for translational medicine as described in Section 15.1.
-. Patients must be offered the opportunity to participate in specimen banking for future research as described in Section 15.1b.2.
---Regulatory Criteria
-Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.
-As a part of the OPEN registration process (see Sections 13.3 and 13.4 for OPEN access instructions) the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.

Publication Information Expand/Collapse

2018

Clinical Trial in Progress: Reversing resistance to PD-1 blockade by combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607 (NCT#02965716)

S Hu-Lieskovan;J Moon;A Lau Clark;K Grossmann;J Sosman;D Campos;M Wu;C Ryan;A Ribas J Clin Oncol 36, 2018 (suppl; abstr TPS9603); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster

Reports & Approvals

Trial Locations

Other Clinical Trials

SWOG Clinical Trial Number
S1801